Press Room
JDRF Honors Prominent Diabetes Researcher with New Award
New York, NY, June 27, 2012—JDRF announced today the creation of the Alan Permutt Career Development Award and the award’s first recipient. The new award was named in honor of the late M. Alan Permutt, MD, a longtime JDRF advocate and researcher, and is being presented to current JDRF Career ...
iCo Therapeutics Featured in JDRF's Top Research Highlights Publication
VANCOUVER, July 3, 2012 /CNW/ - iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug company, is pleased to announce that it has been featured in a JDRF newsletter entitled Top Research Highlights. JDRF is the largest charitable supporter of type 1 diabetes (T1D) and has joined forces ...
KalVista Pharmaceuticals and JDRF form research partnership
Southampton, UK and New York, USA 09 January 2012 - KalVista Pharmaceuticals ("KalVista") and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease. Diabetic ...
Study Aims to Increase Adoption of Advanced Diabetes Technology
London, ON (January 25, 2012) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the London site of the first multi-centre pediatric study in Canada using insulin pump therapy and continuous glucose monitoring (CGM).
JDRF Applauds the Government of Alberta
TORONTO (February 21, 2012) – JDRF applauds the Government of Alberta for expanding coverage for supplies needed by insulin-dependent individuals living with diabetes to monitor their blood glucose and help manage their disease.
Boston Pizza's big hearted guests help raise $614,000
RICHMOND, B.C., March 1, 2012 – Boston Pizza guests shared the love this Valentine’s Day through the restaurant’s 20th annual heart-shaped pizza charity event, which raised more than $614,000 for the Boston Pizza Foundation.
Clinical Trial Seeks to Reduce Cardiovascular Risk in Adults with T1D
London, Ontario (March 2, 2012) − JDRF-funded researchers are currently enrolling adult patients with type 1 diabetes (T1D) in Canada for the REMOVAL (Reducing with MetfOrmin Vascular Adverse Lesions in T1D) study. The study will test whether metformin – ...
Study Aims to Improve Future Kidney and Heart Outcomes
Whitby, Ontario (March 20, 2012) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the expansion of the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) at The Charles H. Best Diabetes Centre in Whitby, Ontario.
Researchers Find Beta Cell Stress Could Trigger the Development of Type 1 Diabetes
NEW YORK, March 22, 2011 --- In type 1 diabetes (T1D), pancreatic beta cells die from a misguided autoimmune attack, but how and why that happens is still unclear. Now, JDRF-funded scientists from the Indiana University School of Medicine have found that a specific type of cellular stress ...
iCo Therapeutics and JDRF Team Up
March 28, 2012, Vancouver, Canada—iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common ...
